Abstract
Monitoring of clinical trials is critical to the protection of human subjects and the conduct of high-quality research. Even though the adoption of risk-based monitoring (RBM) has been suggested for many years, the RBM approach has been less widespread than expected. Centralized monitoring is one of the RMB pillars, together with remote-site monitoring visits, reduced Source Data Verification (SDV) and Source Document Reviews (SDR). The COVID-19 pandemic promoted disruptions in the conduction of clinical trials, as on-site monitoring visits were adjourned. In this context, the transition to RBM by all actors involved in clinical trials has been encouraged. In order to ensure the highest quality of data within a COVID-19 clinical trial, a centralized monitoring tool alongside Case Report Forms (CRFs) and synchronous automated routines were developed at the clinical research platform, Fiocruz, Brazilian Ministry of Health. This paper describes how these tools were developed, their features, advantages, and limitations. The software codes, and the CRFs are available at the Fiocruz Data Repository for Research—Arca Dados, reaffirming Fiocruz’s commitment to Open Science practices.
Publisher
Public Library of Science (PLoS)
Reference22 articles.
1. European Medicines Agency. Guidance on the management of clinical trials during the COVID-19 (Coronavirus) pandemic. 2020.
2. Food and Drug Administration. Guidance for industry: oversight of clinical investigations—a risk-based approach to monitoring. Silver Spring, MD: FDA. 2013.
3. Reflection paper on risk based quality management in clinical trials;European Medicines Agency;Compliance Insp,2013
4. Integrated addendum to ICH E6 (R1): guideline for good clinical practice E6 (R2);IH ICH;Current Step,2015
5. Risk-based monitoring in clinical trials: past, present, and future;B Barnes;Therapeutic innovation & regulatory science,2021